CARVYKTI (cilta-cel) receives FDA approval for multiple myeloma

Legend Biotech / Johnson & Johnson/CARVYKTI (cilta-cel)

CARVYKTI received FDA approval in February 2022 as a treatment for adult patients with relapsed or refractory multiple myeloma after four or more prior therapies, becoming a key therapy in the CAR-T landscape.